



Trubion Pharmaceuticals, Inc. to Present at the BioCentury and Thomson Reuters Future Leaders in the Biotech Industry Conference

SEATTLE, April 5, 2010 /PRNewswire via COMTEX News Network/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced it will present a corporate update at the BioCentury and Thomson Reuters Future Leaders in the Biotech Industry conference to be held at the Millennium Broadway Hotel & Conference Center, 145 West 44th St. in New York City. Michelle Burris, senior vice president and chief operating officer, and Dr. Ken Mohler, senior vice president and chief scientific officer, are scheduled to present on Thursday, April 8, at 1:30 p.m. ET in Room 404/405. The presentation will be available in the investor section of Trubion's website: <http://investors.trubion.com/index.cfm>.

(Logo: <http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO>)

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well as simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: <http://investors.trubion.com/index.cfm>.

TRBN-G

Contact:

Jim DeNike
Senior Director, Corporate Communications
Trubion Pharmaceuticals, Inc.
(206) 838-0500
jdenike@trubion.com
<http://www.trubion.com>

Waggener Edstrom Worldwide Healthcare
Amy Petty
Account Manager
(617) 576-5788
amyp@waggeneredstrom.com

SOURCE Trubion Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved